222 related articles for article (PubMed ID: 25011352)
1. Tolerability during double-blind randomized phase I trials with the house dust mite allergy immunotherapy tablet in adults and children.
Corzo JL; Carrillo T; Pedemonte C; Plaza Martin AM; Martín Hurtado S; Dige E; Calderon MA
J Investig Allergol Clin Immunol; 2014; 24(3):154-61. PubMed ID: 25011352
[TBL] [Abstract][Full Text] [Related]
2. Safety of house dust mite sublingual immunotherapy standardized quality tablet in children allergic to house dust mites.
Maloney J; Prenner BM; Bernstein DI; Lu S; Gawchik S; Berman G; Kaur A; Li Z; Nolte H
Ann Allergy Asthma Immunol; 2016 Jan; 116(1):59-65. PubMed ID: 26553448
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of the SQ house dust mite sublingual immunotherapy tablet in Japanese adults and adolescents with house dust mite-induced allergic rhinitis.
Okubo K; Masuyama K; Imai T; Okamiya K; Stage BS; Seitzberg D; Konno A
J Allergy Clin Immunol; 2017 Jun; 139(6):1840-1848.e10. PubMed ID: 27864024
[TBL] [Abstract][Full Text] [Related]
4. Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial.
Mosbech H; Deckelmann R; de Blay F; Pastorello EA; Trebas-Pietras E; Andres LP; Malcus I; Ljørring C; Canonica GW
J Allergy Clin Immunol; 2014 Sep; 134(3):568-575.e7. PubMed ID: 24797423
[TBL] [Abstract][Full Text] [Related]
5. The SQ House Dust Mite SLIT-Tablet Is Well Tolerated in Patients with House Dust Mite Respiratory Allergic Disease.
Emminger W; Hernández MD; Cardona V; Smeenk F; Fogh BS; Calderon MA; de Blay F; Backer V
Int Arch Allergy Immunol; 2017; 174(1):35-44. PubMed ID: 28950268
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial.
Nolte H; Bernstein DI; Nelson HS; Kleine-Tebbe J; Sussman GL; Seitzberg D; Rehm D; Kaur A; Li Z; Lu S
J Allergy Clin Immunol; 2016 Dec; 138(6):1631-1638. PubMed ID: 27521719
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma: A Randomized Clinical Trial.
Virchow JC; Backer V; Kuna P; Prieto L; Nolte H; Villesen HH; Ljørring C; Riis B; de Blay F
JAMA; 2016 Apr; 315(16):1715-25. PubMed ID: 27115376
[TBL] [Abstract][Full Text] [Related]
8. Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber.
Nolte H; Maloney J; Nelson HS; Bernstein DI; Lu S; Li Z; Kaur A; Zieglmayer P; Zieglmayer R; Lemell P; Horak F
J Allergy Clin Immunol; 2015 Jun; 135(6):1494-501.e6. PubMed ID: 25636947
[TBL] [Abstract][Full Text] [Related]
9. Tolerability of the SQ Tree SLIT Tablet in Adults.
Birk AO; Andersen JS; Villesen HH; Steffensen MA; Calderon MA
Clin Ther; 2017 Sep; 39(9):1858-1867. PubMed ID: 28844318
[TBL] [Abstract][Full Text] [Related]
10. Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomised trial.
Aydogan M; Eifan AO; Keles S; Akkoc T; Nursoy MA; Bahceciler NN; Barlan IB
Respir Med; 2013 Sep; 107(9):1322-9. PubMed ID: 23886432
[TBL] [Abstract][Full Text] [Related]
11. Safety profile of the SQ house dust mite sublingual immunotherapy-tablet in Japanese adult patients with house dust mite-induced allergic asthma: a randomized, double-blind, placebo-controlled phase I study.
Okamiya K; Sekino H; Azuma R; Kudo M; Sakaguchi M; Nemoto F; Muramatsu N; Maekawa Y; Tanaka A
J Asthma; 2019 Dec; 56(12):1347-1355. PubMed ID: 30444150
[No Abstract] [Full Text] [Related]
12. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies.
Calderon MA; Casale TB; Nelson HS; Demoly P
J Allergy Clin Immunol; 2013 Dec; 132(6):1322-36. PubMed ID: 24139829
[TBL] [Abstract][Full Text] [Related]
13. Epinephrine Use in Clinical Trials of Sublingual Immunotherapy Tablets.
Nolte H; Casale TB; Lockey RF; Fogh BS; Kaur A; Lu S; Nelson HS
J Allergy Clin Immunol Pract; 2017; 5(1):84-89.e3. PubMed ID: 27838323
[TBL] [Abstract][Full Text] [Related]
14. Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled phase III trial.
Demoly P; Emminger W; Rehm D; Backer V; Tommerup L; Kleine-Tebbe J
J Allergy Clin Immunol; 2016 Feb; 137(2):444-451.e8. PubMed ID: 26292778
[TBL] [Abstract][Full Text] [Related]
15. Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures.
Pham-Thi N; Scheinmann P; Fadel R; Combebias A; Andre C
Pediatr Allergy Immunol; 2007 Feb; 18(1):47-57. PubMed ID: 17295799
[TBL] [Abstract][Full Text] [Related]
16. Pooled efficacy and safety data for house dust mite sublingual immunotherapy tablets in adolescents.
Matsuoka T; Bernstein DI; Masuyama K; Nolte H; Okamiya K; Seitzberg D; Nelson HS
Pediatr Allergy Immunol; 2017 Nov; 28(7):661-667. PubMed ID: 28660739
[TBL] [Abstract][Full Text] [Related]
17. SQ house dust mite sublingually administered immunotherapy tablet (ALK) improves allergic rhinitis in patients with house dust mite allergic asthma and rhinitis symptoms.
Mosbech H; Canonica GW; Backer V; de Blay F; Klimek L; Broge L; Ljørring C
Ann Allergy Asthma Immunol; 2015 Feb; 114(2):134-40. PubMed ID: 25624131
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamic and pharmacokinetic evaluation of house dust mite sublingually administered immunotherapy tablet in the treatment of asthma.
Mauro M; Boni E; Makri E; Incorvaia C
Expert Opin Drug Metab Toxicol; 2015; 11(12):1937-43. PubMed ID: 26565665
[TBL] [Abstract][Full Text] [Related]
19. Safety profile and immunological response of dual sublingual immunotherapy with house dust mite tablet and Japanese cedar pollen tablet.
Gotoh M; Okubo K; Yuta A; Ogawa Y; Nagakura H; Ueyama S; Ueyama T; Kawashima K; Yamamoto M; Fujieda S; Sakashita M; Sakamoto H; Iwasaki N; Mori E; Endo T; Ohta N; Kitazawa H; Okano M; Asako M; Takada M; Terada T; Inaka Y; Yonekura S; Matsuoka T; Kaneko S; Hata H; Hijikata N; Tanaka H; Masuyama K; Okamoto Y
Allergol Int; 2020 Jan; 69(1):104-110. PubMed ID: 31421989
[TBL] [Abstract][Full Text] [Related]
20. A practical guide to the sublingual immunotherapy tablet adverse event profile: implications for clinical practice.
Bernstein DI; Bardelas JA; Svanholm Fogh B; Kaur A; Li Z; Nolte H
Postgrad Med; 2017 Aug; 129(6):590-597. PubMed ID: 28326906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
